Press Releases

Biogen and Eisai Expand Existing Collaboration Agreement to Develop and Commercialize Investigational Alzheimer’s Disease

Eisai Co., Ltd. and Biogen Inc. announced today that the companies have expanded their existing agreement to jointly develop and commercialize investigational Alzheimer's disease treatments. Under the terms of the agreement Eisai has exercised its option...

Nanobiotix Completes Patient Inclusion for Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma

NANOBIOTIX , a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, announced that it has completed patient inclusion for the Phase II/III trial (Act.In.Sarc) of its lead product candidate, NBTXR3, in soft tissue sarcoma. ...

KalVista Pharmaceuticals Announces Collaboration with Merck

KalVista Pharmaceuticals, Inc , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors announced that it has entered into a collaboration agreement with Merck, known as MSD outside the United States...

EAHP Congress – register as a participant and submit your abstract

Gothenburg in Sweden, a beautiful city with an exciting cultural life will be the destination of the 23rd Congress of the European Association of Hospital Pharmacists (EAHP). Hospital pharmacists from all over the world will be...

Sangamo And Bioverativ Announce FDA Acceptance Of IND Application For ST-400

Sangamo Therapeutics, Inc. the leader in therapeutic genome editing, and Bioverativ Inc. (NASDAQ: BIVV), a global biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for hemophilia and other rare blood disorders, announced today that the...

TrialScope Tackles Issue of “Sharing Clinical Trial Results with Patients” at CBI Conference; Presents Sponsor Survey Findings

TrialScope, the global leader in clinical trial transparency and compliance solutions, announced new findings from its sponsor survey on clinical trial results sharing practices, at CBI’s second annual Plain Language Summit in Philadelphia. The survey asked...

GSK receives approval for Benlysta in Japan for the treatment of systemic lupus erythematosus

GSK announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Benlysta (belimumab) for the treatment of adult patients with systemic lupus erythematosus (SLE) who are inadequate responders to existing therapies. Benlysta is for use...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read